keyword
MENU ▼
Read by QxMD icon Read
search

Bone scans in prostate cancer

keyword
https://www.readbyqxmd.com/read/28526418/prevalence-of-measurable-disease-in-metastatic-castration-resistant-prostate-cancer
#1
Guru Sonpavde, Ankit Madan, Mary K Baker, Jori E May, Gurudatta Naik, Sejong Bae
BACKGROUND: Because of the low historical prevalence of measurable disease in metastatic castration-resistant prostate cancer (mCRPC), phase II trials have used prostate-specific antigen (PSA) and bone scan changes as primary end points. Frequent whole-body imaging and improved computed tomography technology currently identify measurable disease more frequently, warranting consideration of objective response as a major end point. PATIENTS AND METHODS: Data from reported phase III trials of mCRPC were analyzed...
April 26, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28525684/223ra-dichloride-response-in-a-patient-with-paget-disease-and-bone-metastases-secondary-to-castration-resistant-prostate-cancer
#2
Lina García Cañamaque, Cristina Rioja Parada, Paloma García De la Peña
PURPOSE: Paget disease is commonly asymptomatic and discovered when an imaging test is performed for another clinical indication or when elevated serum alkaline phosphatase is found. Bone pain usually appears late in the disease process and is only present in a minority of patients. For diagnosis, X-ray and bone scan are the most recommended imaging methods; radionuclide imaging of the skeleton has become the standard, since it is the most sensitive test for detecting increased bone activity...
May 18, 2017: Tumori
https://www.readbyqxmd.com/read/28507988/comparative-therapeutic-efficacy-of-153-sm-edtmp-and-177-lu-edtmp-for-bone-pain-palliation-in-patients-with-skeletal-metastases-patients-pain-score-analysis-and-personalized-dosimetry
#3
Sarika Sharma, Baljinder Singh, Ashwani Koul, Bhagwant Rai Mittal
INTRODUCTION: The aim of the present study was to compare the therapeutic efficacy of (153)Sm-EDTMP and (177)Lu-EDTMP in pain palliation in cancer patients with skeletal metastases. MATERIALS AND METHODS: Thirty patients (25 M:5 F, mean age: 66.0 ± 14.7 years) of breast/prostate cancer with documented skeletal metastases were recruited prospectively. Twenty patients were considered randomly for treatment with (153)Sm-EDTMP and with (177)Lu-EDTMP in 10 patients, respectively...
2017: Frontiers in Medicine
https://www.readbyqxmd.com/read/28449007/efficacy-of-stereotactic-body-radiotherapy-in-oligorecurrent-and-in-oligoprogressive-prostate-cancer-new-evidence-from-a-multicentric-study
#4
Luca Triggiani, Filippo Alongi, Michela Buglione, Beatrice Detti, Riccardo Santoni, Alessio Bruni, Ernesto Maranzano, Frank Lohr, Rolando D'Angelillo, Alessandro Magli, Alberto Bonetta, Rosario Mazzola, Nadia Pasinetti, Giulio Francolini, Gianluca Ingrosso, Fabio Trippa, Sergio Fersino, Paolo Borghetti, Paolo Ghirardelli, Stefano Maria Magrini
BACKGROUND: The aim of the present study is to evaluate the impact of metastases-directed stereotactic body radiotherapy in two groups of oligometastatic prostate cancer (PC) patients: oligorecurrent PC and oligoprogressive castration-resistant PC (oligo-CRPC). METHODS: Inclusion criteria of the present multicentre retrospective analysis were: (1) oligorecurrent PC, defined as the presence of 1-3 lesions (bone or nodes) detected with choline positron emission tomography or CT plus bone scan following biochemical recurrence; (2) oligo-CRPC, defined as metastases (bone or nodes) detected after a prostatic-specific antigen rise during androgen deprivation therapy (ADT)...
April 27, 2017: British Journal of Cancer
https://www.readbyqxmd.com/read/28443145/initial-single-centre-canadian-experience-with-18f-fluoromethylcholine-positron-emission-tomography-computed-tomography-18f-fch-pet-ct-for-biochemical-recurrence-in-prostate-cancer-patients-initially-treated-with-curative-intent
#5
Simon Gauvin, Yannick Cerantola, Eléonore Haberer, Vincent Pelsser, Stephan Probst, Franck Bladou, Maurice Anidjar
INTRODUCTION: We sought to determine predictive factors (patient and prostate-specific antigen [PSA] characteristics) for 18F-fluoromethylcholine positron emission tomography-computed tomography (18F-FCH PET/CT) positivity in the context of biochemical recurrence after local treatment of prostate cancer (PCa) with curative intent. METHODS: This is a retrospective study including 60 18F-FCH PET/CT scans of patients with biochemical recurrence after initial radical prostatectomy (RP), external beam radiation therapy (EBRT), or focal high-intensity focused ultrasound (HIFU) with curative intent...
January 2017: Canadian Urological Association Journal, Journal de L'Association des Urologues du Canada
https://www.readbyqxmd.com/read/28442297/vertebral-and-femoral-bone-mineral-density-and-bone-strength-in-prostate-cancer-patients-assessed-in-phantomless-pet-ct-examinations
#6
Benedikt J Schwaiger, David L Kopperdahl, Lorenzo Nardo, Luca Facchetti, Alexandra S Gersing, Jan Neumann, Kwang J Lee, Tony M Keaveny, Thomas M Link
PURPOSE: Bone fracture risk assessed ancillary to positron emission tomography with computed tomography co-registration (PET/CT) could provide substantial clinical value to oncology patients with elevated fracture risk without introducing additional radiation dose. The purpose of our study was to investigate the feasibility of obtaining valid measurements of bone mineral density (BMD) and finite element analysis-derived bone strength of the hip and spine using PET/CT examinations of prostate cancer patients by comparing against values obtained using routine multidetector-row computed tomography (MDCT) scans-as validated in previous studies-as a reference standard...
April 24, 2017: Bone
https://www.readbyqxmd.com/read/28417160/diagnosis-of-recurrent-prostate-cancer-with-pet-ct-imaging-using-the-gastrin-releasing-peptide-receptor-antagonist-68-ga-rm2-preliminary-results-in-patients-with-negative-or-inconclusive-18-f-fluoroethylcholine-pet-ct
#7
Gesche Wieser, Ilinca Popp, H Christian Rischke, Vanessa Drendel, Anca-Ligia Grosu, Mark Bartholomä, Wolfgang A Weber, Rosalba Mansi, Ulrich Wetterauer, Wolfgang Schultze-Seemann, Philipp T Meyer, Cordula Annette Jilg
PURPOSE/BACKGROUND: [(18)F]fluoroethylcholine ((18)FECH) has been shown to be a valuable PET-tracer in recurrent prostate cancer (PCa), but still has limited accuracy. RM2 is a gastrin-releasing peptide receptor (GRPr) antagonist that binds to GRPr on PCa cells. Recent studies suggest that GRPr imaging with PET/CT is a promising technique for staging and restaging of PCa. We explore the value of GRPr-PET using the (68)Ga-labeled GRPr antagonist RM2 in a selected population of patients with biochemically recurrent PCa and a negative/inconclusive (18)FECH-PET/CT...
April 18, 2017: European Journal of Nuclear Medicine and Molecular Imaging
https://www.readbyqxmd.com/read/28390646/first-line-management-of-metastatic-castrate-resistant-prostate-cancer-patients-audit-of-real-life-practices
#8
Anthony Turpin, David Pasquier, Christophe Massard, Jean-François Berdah, Stéphane Culine, Nicolas Penel
BACKGROUND: No reliable guidelines are available for choosing the best option between docetaxel and new hormonal therapies (NHTs) (i.e., abiraterone and enzalutamide) in first-line therapy for metastatic castration-resistant prostate cancer (mCRPC) patients. We performed an audit of real-life practices. METHODS: We built an online questionnaire and distributed it with the help of French oncology networks. This questionnaire was sent to 481 physicians who treat patients with mCRPC...
April 5, 2017: Bulletin du Cancer
https://www.readbyqxmd.com/read/28379896/spectrum-of-metastatic-and-nonmetastatic-skeletal-findings-with-dual-phase-18f-fech-pet-ct-in-patients-with-biochemical-relapse-of-prostate-cancer
#9
Athar Haroon, Rizwan Syed, Raymond Endozo, Rayjanah Allie, Alex Freeman, Mark Emberton, Jamshed Bomanji
INTRODUCTION: The aim of this study was to evaluate the spectrum of skeletal findings on dual-phase fluorine-18-fluoroethylcholine (F-FECH) PET/CT performed during the work-up of patients referred for suspected prostate cancer relapse. MATERIALS AND METHODS: Three hundred F-FECH PET/CT scans were evaluated prospectively. The low-dose CT features of all cases were categorized as isodense, sclerotic, lytic or mixed lytic/sclerotic and maximum standardized uptake value (SUVmax) values were calculated...
May 2017: Nuclear Medicine Communications
https://www.readbyqxmd.com/read/28317247/establishing-the-pathways-and-indications-for-performing-isotope-bone-scans-in-newly-diagnosed-intermediate-risk-localised-prostate-cancer-results-from-a-large-contemporaneous-cohort
#10
Gokul Vignesh KandaSwamy, Adam Bennett, Krishna Narahari, Owen Hughes, John Rees, Howard Kynaston
OBJECTIVE: To establish the pattern of isotope bone scan (BS) positivity in a large contemporaneous cohort of newly diagnosed localised prostate cancer (PCa) patients and compare with the European Association of Urology (EAU) guidelines. BACKGROUND: Imaging guidelines and clinical practice of using BS to stage newly diagnosed patients with intermediate risk (IR) localised PCa are not uniform in the literature. PATIENTS AND METHODS: All newly diagnosed PCa patients were discussed in a specialist multidisciplinary team (sMDT) meeting and were prospectively entered in a database...
March 20, 2017: BJU International
https://www.readbyqxmd.com/read/28296775/giant-hepatic-metastasis-in-a-patient-with-coin-like-small-cell-lung-carcinoma-incidentally-diagnosed-at-autopsy-a-case-report
#11
Decebal Fodor, Simona Gurzu, Anca Otilia Contac, Ioan Jung
RATIONALE: Encephalopathy is a rare complication of hepatic metastases. In this paper we present a case of a patient with lung cancer and metastatic-related giant hepatomegaly. PATIENT CONCERNS: A 78-year-old previously healthy male was admitted in the Emergency room in hepatic coma. DIAGNOSES: The abdominal CT scan examination revealed a huge liver filled with solid nodules. INTERVENTIONS: No interventions were performed...
March 2017: Medicine (Baltimore)
https://www.readbyqxmd.com/read/28289967/a-pilot-trial-evaluating-zoledronic-acid-induced-changes-in-18-f-fmau-positron-emission-tomography-imaging-of-bone-metastases-in-prostate-cancer
#12
Ulka N Vaishampayan, Omid S Tehrani, Jawana M Lawhorn-Crews, Lance K Heilbrun, Kimberlee Dobson, Daryn Smith, Brenda Dickow, Anthony F Shields
PURPOSE: We conducted a pilot trial utilizing [(18)F]FMAU [1-(2'-deoxy-2'-[(18)F]fluoro-β-D-arabinofuranosyl thymine] as a tumor tracer in positron emission tomography (PET) and evaluated its reproducibility, and changes in maximum and peak standardized uptake value (SUVmax and SUVpeak) with zoledronic acid treatment in castrate resistant prostate cancer (CRPC) patients with bone metastases (BM). PROCEDURES: Eligible patients had CRPC with radiographic evidence of BM and creatinine clearance >30 ml/min...
March 13, 2017: Molecular Imaging and Biology: MIB: the Official Publication of the Academy of Molecular Imaging
https://www.readbyqxmd.com/read/28285790/diagnosis-and-treatment-for-clinically-localized-prostate-cancer-adherence-to-the-european-association-of-urology-clinical-guidelines-in-a-nationwide-population-based-study-gescap-group
#13
F Gómez-Veiga, A Rodríguez-Antolín, B Miñana, C Hernández, J F Suárez, J M Fernández-Gómez, M Unda, J Burgos, A Alcaraz, P Rodríguez, R Medina, J Castiñeiras, C Moreno, E Pedrosa, J M Cózar
OBJECTIVE: To assess the adherence to European Association of Urology (EAU) guidelines in the management of prostate cancer (PCa) in Spain. PATIENTS AND METHODS: Epidemiological, population-based, study including a national representative sample of 3,918 incident patients with histopathological confirmation during 2010; 95% of the patient's sample was followed up for at least one year. Diagnosis along with treatment related variables (for localized PCa -low, intermediate, high and locally-advanced by D'Amico risk stratification) was recorded...
March 9, 2017: Actas Urologicas Españolas
https://www.readbyqxmd.com/read/28278446/fluorocholine-pet-ct-predicts-skeletal-progression-skeletal-event-and-cancer-specific-survival-in-patients-with-biochemical-relapse-for-prostate-cancer
#14
Fabio Zattoni, Emanuela Agostini, Francesco Cattaneo, Marco Maruzzo, Umberto Basso, Filiberto Zattoni, Laura Evangelista
PURPOSE: The aim of our study is to evaluate the prognostic impact of (18)F-Choline (FCh) positron emission tomography (PET)/computed tomography (CT), CT alone and methylene diphophonate bone scan (MDP-BS) in prostate cancer (PCa) patients with biochemical relapse. METHODS: We retrospectively selected 58 patients who underwent, between June 2010 and February 2013, both FCh-PET/CT and MDP-BS within a maximum time interval of 5months. All patients had a biochemical PCa recurrence after radical prostatectomy and/or radiation therapy...
May 2017: Clinical Imaging
https://www.readbyqxmd.com/read/28267456/clinical-experience-with-18-f-labeled-small-molecule-inhibitors-of-prostate-specific-membrane-antigen
#15
REVIEW
Steven P Rowe, Michael A Gorin, Roberto A Salas Fragomeni, Alexander Drzezga, Martin G Pomper
Prostate cancer (PCa) is the most common noncutaneous malignancy diagnosed in men. Despite the large number of men who will suffer from PCa at some point during their lives, conventional imaging modalities for this important disease (contrast-enhanced computed tomography, bone scan, and MR imaging) have provided only marginal to moderate success in appropriately guiding patient management in certain clinical contexts. In this review, the authors discuss radiofluorinated small molecule radiotracers that have been developed to bind to the transmembrane glycoprotein prostate-specific membrane antigen, a target that is nearly universally overexpressed on PCa epithelial cells...
April 2017: PET Clinics
https://www.readbyqxmd.com/read/28265811/expert-system-for-bone-scan-interpretation-improves-progression-assessment-in-bone-metastatic-prostate-cancer
#16
Fabian Haupt, Georg Berding, Ali Namazian, Florian Wilke, Alena Böker, Axel Merseburger, Lilli Geworski, Markus Antonius Kuczyk, Frank Michael Bengel, Inga Peters
INTRODUCTION: The bone scan index (BSI) was introduced as a quantitative tool for tumor involvement in bone of patients with metastatic prostate cancer (mPCa). The computer-aided diagnosis device for BSI analysis EXINIbone(BSI) seems to represent technical progress for the quantitative assessment of bone involvement. But it is not yet clear if the automated BSI (aBSI) could contribute to improved evaluation of progression in patients under antiandrogens or chemotherapy in contrast to the visual interpretation and/or conventional biomarkers such as the prostate-specific antigen (PSA)...
April 2017: Advances in Therapy
https://www.readbyqxmd.com/read/28258616/focal-salvage-high-intensity-focused-ultrasound-in-radiorecurrent-prostate-cancer
#17
Abi Kanthabalan, Max Peters, Marco Van Vulpen, Neil McCartan, Richard Graham Hindley, Amr Emara, Caroline M Moore, Manit Arya, Mark Emberton, Hashim Uddin Ahmed
OBJECTIVE: To assess short- to medium-term cancer control rates and side effects of focal salvage high- intensity focused ultrasound (HIFU). MATERIALS AND METHODS: A retrospective registry analysis identified 150 men who underwent focal salvage HIFU (FS-HIFU) (Sonablate 500) between November 2006 and August 2015. Metastatic disease was excluded by nodal assessment on the pelvic MRI, a radioisotope bone scan and positron-emission tomography (PET) imaging (choline-18F-fluorodeoxyglucose PET or choline PET-CT)...
March 4, 2017: BJU International
https://www.readbyqxmd.com/read/28244493/imaging-response-during-therapy-with-radium-223-for-castration-resistant-prostate-cancer-with-bone-metastases-analysis-of-an-international-multicenter-database
#18
D Keizman, M O Fosboel, H Reichegger, A Peer, E Rosenbaum, M-C Desax, V Neiman, P M Petersen, J Mueller, R Cathomas, M Gottfried, H Dresler, D Sarid, W Mermershtain, K Rouvinov, J Mortensen, S Gillessen, G Daugaard, A Omlin
BACKGROUND: The imaging response to radium-223 therapy is at present poorly described. We aimed to describe the imaging response to radium-223 treatment. METHODS: We retrospectively evaluated the computed tomography (CT) and bone scintigraphy response of metastatic castration-resistant prostate cancer (CRPC) patients treated with radium-223, in eight centers in three countries. RESULTS: A total of 130 patients were included, the majority (n=84, 65%) received radium-223 post docetaxel...
February 28, 2017: Prostate Cancer and Prostatic Diseases
https://www.readbyqxmd.com/read/28217018/skeletal-metastases-presenting-as-superscan-on-technetium-99m-methylene-diphosphonate-whole-body-bone-scintigraphy-in-different-type-of-cancers-a-5-year-retro-prospective-study
#19
P Ram Manohar, Tanveer A Rather, Shoukat H Khan, Dharmender Malik
The purpose of the study is to find out the overall incidence of superscan among different type of cancers, causes of superscan and its relationship with other parameters such as age, sex, duration of disease, and serum alkaline phosphatase (ALP) levels. This was a retro-prospective study. Records of all previous bone scans and reported patients of superscan were re-evaluated retrospectively. Patients who were diagnosed as having superscan in the preceding 3 years with confirmed histopathological diagnosis were included in the retrospective group...
January 2017: World Journal of Nuclear Medicine
https://www.readbyqxmd.com/read/28217016/prostate-specific-antigen-as-a-risk-factor-for-skeletal-metastasis-in-native-ethnic-african-men-with-prostate-cancer-a-case-control-study
#20
Ayman M Qureshi, Khalid Makhdomi, William Stones
Prostate cancer is the most common noncutaneous cancer in males. Men of African origin are at a significantly higher risk as reflected in the higher incidence and mortality rates in this racial group. Metastases incidence increases parallel to serum levels of prostate-specific antigen (PSA), contributing significantly to morbidity and mortality. Staging of the disease involves bone scans, which are sensitive in detecting skeletal metastases. Suggestions that these scans may be omitted in some situations in patients with low prostate specific antigen levels have drawn attention to the matter...
January 2017: World Journal of Nuclear Medicine
keyword
keyword
63986
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"